2009;23:231–240. Comparative efficacy and safety of different hemostatic medications during spinal surgery: A network meta-analysis. 2023 Apr 17. doi: 10.1007/s00266-023-03346-7. Epub 2022 Jul 17. Epub 2015 Jan 21. Goobie SM. 2017;118:293–295. doi: 10.1002/14651858.CD009733.pub3. 72. 2015;2015:874920. Adv Emerg Nurs J. Dobson GP, Doma K, Letson HL. J Trauma Acute Care Surg. Alfitian J, Scheyerer MJ, Rohde A, Schick V, Kammerer T, Schier R. Arch Orthop Trauma Surg. Lancet. Anaesthesia. Severe Trauma-Induced Coagulopathy: Molecular Mechanisms Underlying Critical Illness. Tranexamic Acid and Intraoperative and Postoperative Accumulative Bleeding in Elective Degenerative Spine Surgery. J Trauma Acute Care Surg. Some error has occurred while processing your request. 1. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. 60. 2016;20:100. 82. In particular, its potential thromboembolic side effects may raise concerns with its indiscriminate use. 24. Johnston LR, Rodriguez CJ, Elster EA, Bradley MJ. Findings from this systematic review and meta-analysis of 216 studies suggested that intravenous TXA, irrespective of dosing, is not associated with increased risk of any TE. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. 2019;30:1–10. Anesth Analg. Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): a single-centre, randomised, double-blind, placebo-controlled trial. Keywords: Air Med J. 2011;377:1096–1101, 1101 e10911092. It works by blocking the breakdown of blood clots. Intravenous administration is necessary only if it is difficult to give adequate doses by mouth. J Trauma Acute Care Surg. Anesthesiology. Raveh Y, Souki F, Livingstone J, et al. Injury at the injection site. Shakur H, Roberts I, Bautista R, et al. 52. Crit Care. Concerning perioperative use, a recent meta-analysis of Yates et al6 including 268 randomized controlled trials (RCTs) concluded that “72% of perioperative TXA RCTs excluded patients with major comorbidities and that 59% of RCTs excluded patients with a history of thromboembolic events,” and “there were wide CIs around the risk of a venous thromboembolism (VTE), meaning that the possibility of increased VTE rates in patients with a previous history of thrombotic events cannot be confidently excluded, and there is insufficient evidence on TXA safety in these patients to make definitive recommendations for use of antifibrinolytic therapy.” The statement that TXA does not cause thromboembolic effects is not a proven fact but is rather based on “moderate quality evidence,”6,75 and there is “a need for additional investigation…before strong recommendations can be made.6”. The recommended standard dose is 1 to 1.5 gm or 5-10 ml by slow intravenous injection at a rate of 1 ml/minute, two to three times daily. 10. Influence of fibrinolysin on shock. Statistical significance versus clinical significance. 129(6):1459-1461, December 2019. Table 1 summarizes the statistical analyses of CRASH-2,1 the CRASH-2 follow-up,29 and the WOMAN trial.30 The “no effect” occurs when the CIs of RRs approach 1.0, indicating reduced clinical relevance despite statistically significant differences denoted by a low P value.10 As outlined in Table 1, the upper CI limit of most results is very close to or includes the null value of 1.80 In terms of statistics, the reported differences might be marginal at best.10,80 As the P value is strongly affected by sample size,78–80 these small differences may become statistically significant when the sample size is large enough but irrespective of clinical relevance.10,80–82 In the WOMAN trial, the initially planned sample size was changed and increased during the recruitment from 15,000 to >20,000 subjects. Zahnentfernung bei Hämophilie. 2019;59:806–824. 40. J Trauma Acute Care Surg. JAMA. World Health Organisation (WHO). PMC Zhang P, Liang Y, Chen P, Fang Y, He J, Wang J. 2019;20:443–453. 14. 2019;32:343–352. Tranexamic acid in civilian trauma care in the California prehospital antifibrinolytic therapy study. Patients and physicians are more influenced by RR ratios rather than by absolute risk ratios.81 The presented studies on the use of TXA are examples of the frequent but potentially misleading mixture of absolute and relative effects. 2023 Mar 3;102(9):e32923. Trafimow D, Marks M. Editorial. In contrast, hypocoagulable patients display a high percentage of mortality due to traumatic brain injury (TBI) and septic, thrombotic, or organ failure.71 While every surviving hyperfibrinolytic patient switches to a hypofibrinolytic, prothrombotic state within 24 hours, the switch from a hypofibrinolytic to a hyperfibrinolytic phenotype is rarely encountered.65 The concept of fSD is not new and was identified as a potential driver of irreversible shock after hemorrhage by Hardaway and Johnson72 already back in 1963.8 The potential mechanisms that are discussed around fSD may include platelet activation, resulting in early increased levels of plasminogen activator inhibitor 1 (PAI-1) acutely after injury or low tPA activity from impaired generation after injury.8,9 An increased risk for fSD among severely injured trauma patients receiving TXA has been described (RR = 1.65 [95% CI, 11.10–1.64]; P = .004).70 Thus, the nondiscriminative and liberal administration of an antifibrinolytic agent to a patient population that could be largely in a hypofibrinolytic state does not seem to be physiologically or pharmacologically sound and would potentially expose patients to a higher risk for thromboembolic complications (eg, see Table 4). The first trial to assess and demonstrate a positive effect of TXA when given early and during the prehospital phase of care to trauma patients with signs of hemorrhagic shock was the California Prehospital Antifibrinolytic Therapy (Cal-PAT) trial.42 This trial was conducted as a prospective, multicenter, observational, and nonrandomized cohort. Br J Anaesth. Curr Opin Anaesthesiol. Synthetic antifibrinolytic medications such as tranexamic acid (TXA) may reduce blood transfusion requirements and postoperative complications follo … The present article aims to provide a critical reappraisal of TXA use over the last decade and a “thought exercise” in the potential downsides of TXA. Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. PMC 2013;74:1575–1586. Medicine (Baltimore). Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Efficacy of tranexamic acid on surgical bleeding in spine surgery: a meta-analysis. Lier, Heiko MD*; Maegele, Marc MD†; Shander, Aryeh MD‡, From the *Department of Anesthesiology and Intensive Care Medicine, University Hospital of Cologne, Cologne, Germany, †Department for Traumatology and Orthopedic Surgery, Cologne-Merheim Medical Center, University Witten/Herdecke, Campus Cologne-Merheim, Cologne, Germany. Do all trauma patients benefit from tranexamic acid? 2016;70:129–133. Shock. Grassin-Delyle S, Theusinger OM, Albrecht R, et al. 2015;261:390–394. 44. Cochrane Central Register of Controlled Trials and MEDLINE were searched for eligible studies investigating intravenous TXA and postinterventional outcome published between 1976 and 2020. 2014;120:639–649. Reported Absolute and Relative Reductions of Mortality With TXA Treatment in CRASH-2, Trials in the Trauma Setting Which Have Reported on Side Effects of TXA. The outcome of civilian trauma patients treated with TXA in developed trauma settings and centers does not follow the outcome reported in the CRASH-2 or MATTERs trials.57,58 Neither the CRASH-2 nor the WOMAN trials recorded a reduction in transfusion rates or volumes in patients treated with TXA. Federal government websites often end in .gov or .mil. While TXA has been around for years, its clinical use increased exponentially from a decade ago following the publication of several studies, with one involving >20,000 patients.1 In parallel to this reemergence, concerns about potential side effects were raised and continued to be raised in more recent years.2–6 In our opinion, a rather noncritical interpretation of the study results and a common misunderstanding of TXA as an antihemorrhagic (instead of antifibrinolytic) agent have misled some colleagues to promote indiscriminate use of TXA in a range of therapeutical and increasingly also prophylactic scenarios. 2023 Apr 12;24(8):7118. doi: 10.3390/ijms24087118. 54. Main outcomes and measures: An official website of the United States government. Patients, caregivers, and those assessing outcomes were . 74. J Trauma Acute Care Surg. Sentilhes L, Mattuizzi A, Deneux-Tharaux C. JAMA Surg. Tranexamsaeure is an antifibrinolytic agent. 2013;100:1271–1279. Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE. 2013;117:767–772. 2019 May 8 [Epub ahead of print]. Packungen mit 10 Typ-I-Glasampullen zu 10 ml mit je 1.000 mg Tranexamsäure im Umkarton. Statistical significance versus clinical importance of observed effect sizes: what do P values and confidence intervals really represent? J Blood Transfus. Der Einsatz von Tranexamsäure hat in den letzten Jahren in weiten Bereichen an Bedeutung gewonnen und wird u. a. in den Leitlinien Polytrauma und postpartale Hämorrhagie empfohlen [3-5].In neueren Studien wird der standardisierte Einsatz bei nicht herzchirurgischen Patienten kritisch hinterfragt und ein individualisiertes Vorgehen, das mögliche Vorteile gegen . In addition, an increased risk for vascular occlusive events was not found in studies including patients with a history of thromboembolism. Results: 63. Irl H, Kratzer S, Schwerin S, et al. The administration of TXA was associated with reduced mortality in some34,36,91 and increased mortality in others,2,92,94,95 while no effect on mortality was reported by 1 trial.93 In most of these studies, the TXA cohort was more severely injured, but those cohorts are quite similar to the trauma patients currently being considered as candidates for TXA administration according to the updated recommendations.38–40 The data presented in Table 4 suggest a correlation and not necessarily a causality. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. 2015;78:905–909. Please try after some time. To examine the association between intravenous TXA and total thromboembolic events (TEs) and mortality in patients of all ages and of any medical disciplines. Epub 2022 Jun 16. Table 2 summarizes the chronology of the landmark TXA studies published to date. Figure.. Tranexamic acid dosage for spinal surgery: a meta-analysis. Chemie Das Molekül besitzt die Summenformel : C 8 H 15 NO 2 RCT indicates randomized clinical trial; TXA, tranexamic acid. 2022 Jan 1;157(1):79-80. doi: 10.1001/jamasurg.2021.4138. Contribution: This author helped edit the text; acquire, analyze, and interpret the data; and revise the manuscript. Rote Liste Fachinformation (German SmPC). TXA diffuses quickly into the synovia and other tissues and is distributed throughout all tissues.7,19 Around 10% of the plasma concentration can be found in the cerebrospinal fluid and 1% in mother’s milk.7,19 TXA is eliminated unchanged via glomerular filtration and excreted in the urine within 2 to 3 hours after administration.7,19 The antifibrinolytic effects of TXA may last up to 7 or 8 hours. 2017;5:5. Adolescent under 15 years: 15 mg/kg . Federal government websites often end in .gov or .mil. 2013;39:121–126. AKI = acute kidney injury; aOR = adjusted odds ratio; aPC = activated protein C BPsyst = systolic blood pressure; BW = body weight Cal-PAT = California Prehospital Antifibrinolytic Therapy; CI = confidence interval CRASH-2 = Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage-2; DVT = deep vein thrombosis; EACA = ε-aminocaproic acid; ENT = ear/nose/throat; fSD = fibrinolytic shutdown; GABA = γ-aminobutyric acid; HR = hazard rate; IDF = Israel Defense Forces; ISS = injury severity score Ly30 = lysis after 30 minutes; MATTERs = Military Application of Tranexamic Acid in Trauma Emergency Resuscitation study; MOF = multiorgan failure; NHS = National Health Services; NMDA = N-Methyl-d-aspartic acid; NNT = number needed to treat; OR = odds ratio PAI 1/2 = plasminogen activator inhibitor 1 (endothelium) and 2 (placenta); PAP = plasmin–antiplasmin pat. Accessibility Spine J. Anesthesiology. Prescribers’ Digital Reference (PDR). Meta-analysis, subgroup and sensitivity analysis, and meta-regression were performed. Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis. 2017;43:224–234. The electronic database search yielded a total of 782 studies, and 381 were considered for full-text review. Prehospital tranexamic acid: what is the current evidence? Binz S, McCollester J, Thomas S, et al. Clin Pharmacokinet. Fibrinolysis shutdown is associated with thrombotic and hemorrhagic complications and poorer outcomes after liver transplantation. Thromb Haemost. J Trauma Acute Care Surg. Available at: 32. 37. Similarly, the Israel Defense Forces (IDF), which are also responsible for civilian trauma care in their national setting, concluded from their experience with TXA that “there is likely a benefit in the civilian sector as well” for this agent.35 In their prospective data collection from severely injured trauma patients, Cole et al36 further addressed the indications for TXA. Address correspondence to Heiko Lier, MD, Department of Anesthesiology and Intensive Care Medicine, University Hospital of Cologne, Kerpener Straße 62, D-50937 Cologne, Germany. Anesthesiology. Tranexamsäure Eberth is available only with your doctor's prescription. 42. Roberts I, Prieto-Merino D, Manno D. Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. After the 3-hour window, no beneficial effect with TXA was observed. 39. Trends Cardiovasc Med. 65. In the setting of ongoing hemorrhage, blood loss may become a significant route of drug elimination.55. Please enable it to take advantage of the complete set of features! doi: 10.1001/jamanetworkopen.2022.0625. Mortality and thrombosis in injured adults receiving tranexamic acid in the post-CRASH-2 era. Online ahead of print. Ducloy-Bouthors AS, Duhamel A, Kipnis E, et al. Here, we aim to provide a critical reappraisal of TXA clinical use, a “thought exercise” in the potential downsides of TXA, based on publications that might sensitize the readers for a more cautious approach. 2017;815:49–55. The .gov means it’s official. Shock. Besides these studies listed, a range of small- to medium-sized publications conducted in different clinical settings has been published following CRASH-2.